Anti-CGRP Monoclonal Antibodies Market Estimations (2025 - 2035)

Anti-CGRP Monoclonal Antibodies Market Estimations (2025 - 2035)

The anti-CGRP monoclonal antibodies market covers monoclonal antibodies that block calcitonin gene-related peptide or its receptor for migraine prevention, including erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality) and eptinezumab (Vyepti), given by subcutaneous injection or intravenous infusion, for episodic migraine, chronic migraine and cluster headache in adults and, for fremanezumab, children.

📄Report ID:2507 | 📊Format: Databook | 📅Published: 18 November 2026 | ⚡Delivery: Immediate